Innogenetics and Takeda enter into License Agreement on Takeda's beta-amyloid antibody patents for Alzheimer's Disease
Gent. Innogenetics announced that Innogenetics and Takeda Chemical Industries, Ltd., Osaka, Japan ("Takeda") have entered into a worldwide licensing agreement by which Innogenetics gains access to Takeda's patent rights for the diagnostic and research use of beta-amyloid antibodies. The financial terms of this agreement were not disclosed.
The abnormal accumulation of beta-amyloid protein in the brain is one of the two pathological hallmarks of Alzheimer's disease, and represents a particularly useful diagnostic marker for the disease.
Innogenetics is one of the pioneers in the development and commercialization of novel biochemical markers (biomarkers) for the early and differential diagnosis of Alzheimer's disease and other neurodegenerative disorders.
"This significant license agreement with Takeda strengthens and complements Innogenetics' position in the field of neurodegenerative biomarkers," added Philippe Archinard, Chief Executive Officer of Innogenetics. "The addition of Takeda's beta-amyloid-related patent rights to our proprietary Tau and phospho-Tau patent portfolios underscores Innogenetics' leadership position in the development and marketing of novel diagnostic tools for better and earlier patient diagnosis, and for accelerated drug development."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous